# Rosanne Lane

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/rosanne-lane/

## Facts

| Field | Value |
| --- | --- |
| Citations | 6,657 |
| Field | Treatment of Major Depression |
| h-index | 28 |
| i10-index | 35 |
| Last Known Institution | Johnson & Johnson (United States) |
| OpenAlex ID | https://openalex.org/A5109293494 |
| Works | 53 |

## Researcher papers

- [Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study](https://scholariq.org/papers/efficacy-and-safety-of-flexibly-dosed-esketamine-nasal-spray-combined-with-a/)
- [Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression](https://scholariq.org/papers/efficacy-of-esketamine-nasal-spray-plus-oral-antidepressant-treatment-for/)
- [Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study](https://scholariq.org/papers/efficacy-and-safety-of-intranasal-esketamine-for-the-rapid-reduction-of-symptoms/)
- [Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)](https://scholariq.org/papers/efficacy-and-safety-of-fixed-dose-esketamine-nasal-spray-combined-with-a-new/)
- [Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3](https://scholariq.org/papers/efficacy-and-safety-of-esketamine-nasal-spray-plus-an-oral-antidepressant-in/)
- [Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)](https://scholariq.org/papers/esketamine-nasal-spray-for-rapid-reduction-of-depressive-symptoms-in-patients/)
- [Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent](https://scholariq.org/papers/esketamine-nasal-spray-for-rapid-reduction-of-major-depressive-disorder-symptoms/)
- [An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: A randomized, double-blind, placebo-controlled trial with tocolytic rescue](https://scholariq.org/papers/an-oxytocin-receptor-antagonist-atosiban-in-the-treatment-of-preterm-labor-a/)
- [Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression](https://scholariq.org/papers/esketamine-nasal-spray-plus-oral-antidepressant-in-patients-with-treatment/)
- [Topiramate monotherapy in the management of acute mania: results of four double‐blind placebo‐controlled trials](https://scholariq.org/papers/topiramate-monotherapy-in-the-management-of-acute-mania-results-of-four-double/)
- [Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant](https://scholariq.org/papers/meaningful-change-in-depression-symptoms-assessed-with-the-patient-health/)

## Researcher topics

- [Treatment of Major Depression](https://scholariq.org/topics/treatment-of-major-depression/)
- [Schizophrenia research and treatment](https://scholariq.org/topics/schizophrenia-research-and-treatment/)
- [Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes](https://scholariq.org/topics/anxiety-depression-psychometrics-treatment-cognitive-processes/)
- [Neurotransmitter Receptor Influence on Behavior](https://scholariq.org/topics/neurotransmitter-receptor-influence-on-behavior/)
- [Tryptophan and brain disorders](https://scholariq.org/topics/tryptophan-and-brain-disorders/)

## Researcher university

- [Johnson & Johnson (United States)](https://scholariq.org/institutions/johnson-and-johnson-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.